Determining the effectiveness of Fibrin Sealants in reducing complications in patients undergoing lateral neck dissectio

Not Applicable

Completed

• Conditions: Head and neck cancer; Cancer; Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissues

• Registration Number: ISRCTN99181100
• Lead Sponsor: niversity of Liverpool

Brief Summary

2020 Protocol article in https://pubmed.ncbi.nlm.nih.gov/32509321/ protocol (added 23/11/2020) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37894440/ (added 30/10/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-05-16
• Study Completion: 2019-10-09
• Last Update Posted: 13 November 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 51

Inclusion Criteria

1. Patients due to undergo lateral neck dissection
2. Neck dissection to include a minimum of 3 levels
3. Patients who have capacity to consent

Exclusion Criteria

1. Known allergy to Aprotinin (an ingredient of Fibrin Sealants known to cause allergic reactions)
2. Pregnancy or breastfeeding
3. Age less than 18 years
4. Bilateral neck dissection
5. Previous exposure to Fibrin Sealant within the last 6 months
6. The patient has a cancer that requires complex reconstructive surgery
7. Allergy to dairy products

Study & Design

• Study Type: Interventional
• Study Design: Not specified